Furin as a therapeutic target in cystic fibrosis airways disease.

Journal Information

Full Title: Eur Respir Rev

Abbreviation: Eur Respir Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest: S.L. Martin has received research grants from Boston Pharmaceuticals, who have a furin inhibitor programme in development. The remaining authors have no conflicts to disclose."

Evidence found in paper:

"Support statement: L.E.J. Douglas is supported by a project grant funded by Boston Pharmaceuticals and B.M. Montgomery by a collaborative PhD studentship funded by the Department of the Economy, Northern Ireland and Boston Pharmaceuticals (to S.L. Martin). J.A. Reihill is funded via an MRC Innovation Scholar Award (grant reference MR/W004135/1 to J.A. Reihill and S.L. Martin). Funding information for this article has been deposited with the Crossref Funder Registry."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025